Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population

  1. Hitoshi Kawasuji
  2. Yoshitomo Morinaga
  3. Hideki Tani
  4. Yumiko Saga
  5. Makito Kaneda
  6. Yushi Murai
  7. Akitoshi Ueno
  8. Yuki Miyajima
  9. Yasutaka Fukui
  10. Kentaro Nagaoka
  11. Chikako Ono
  12. Yoshiharu Matsuura
  13. Hideki Niimi
  14. Yoshihiro Yamamoto

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1016/j.jiac.2022.05.009
  2. ScreenIT

    SciScore for 10.1101/2022.02.23.22271433: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsIRB: Ethics approval: This study was performed in accordance with the Declaration of Helsinki and was approved by the ethical review board of the University of Toyama (approval No.: R2019167).
    Consent: Written informed consent was obtained from all the participants.
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    The serum concentration of the anti-RBD antibody in serum samples was measured using the Elecsys Anti-SARS-CoV-2 S immunoassay (Roche Diagnostics GmbH, Basel, Switzerland) at Toyama University Hospital.
    anti-RBD
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    After incubation, VeroE6/TMPRSS2 cells (JCRB1819) were treated with DMEM-containing serum and pseudotyped viruses.
    VeroE6/TMPRSS2
    suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
    Recombinant DNA
    SentencesResources
    The expression plasmid for the truncated S protein of SARS-CoV-2 and pCAG-SARS-CoV-2 S (Wuhan) was provided by Dr. Shuetsu Fukushi of the National Institute of Infectious Diseases, Japan. pCAGG-pm3-SARS2-Shu-d19-B1.617.2 (Delta-derived variant) and pCAGG-pm3-SARS2-Shu-d19-BA.1_EPE_3mut_Omi (Omicron-derived variant) were also generated, as previously described [14]
    pCAG-SARS-CoV-2
    suggested: None
    pCAGG-pm3-SARS2-Shu-d19-B1.617.2
    suggested: None
    pCAGG-pm3-SARS2-Shu-d19-BA.1_EPE_3mut_Omi
    suggested: None
    VSVs bearing envelope (G) (VSV-G) were also generated as a control.
    VSV-G
    suggested: RRID:Addgene_138479)
    Software and Algorithms
    SentencesResources
    Data were analyzed using GraphPad Prism version 9.3.1
    GraphPad Prism
    suggested: (GraphPad Prism, RRID:SCR_002798)
    1 (GraphPad Software, San Diego, CA).
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    The limitation of this study is that the participants were limited to 20-69 years old, and the exact recovery for older and younger people who have been vaccinated is unknown. In addition, detailed interviews regarding specific underlying diseases and medications were not conducted. Thus, the elderly and those with underlying illnesses are considered to be at a higher risk of COVID-19 until their follow-up reports are available. In conclusion, the present study showed that the booster effect, especially against the Omicron variant, was observed in the Japanese population. Since booster vaccination is now ongoing in the elderly, followed by healthcare workers in Japan, the findings contribute to the correct understanding of the efficacy and side effects of the booster and the promotion of vaccine campaigns.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2022.02.23.22271433 on medRxiv